Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Anadys has A-site in mind

Having recently moved into preclinical development with leads from its Ribosome A-site program, Anadys Pharmaceuticals Inc. is on the verge of validating its RNA targeting capabilities - an important inflection point considering 40% of its R&D efforts are focused on RNA targets.

Despite its involvement in many biological processes, RNA has only recently been considered a drug target because of technical

Read the full 616 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers